Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Jun Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9957-9208; OpenAlex author ID A5100384671. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 5 papers · 2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 3 papers

Papers 13

  1. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer [Cancer Lett. 502 (2021) 9-24]. Co-author DOI 10.1016/j.canlet.2024.216697↗
  2. Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models. Co-author DOI 10.1016/j.xphs.2023.10.019↗
  3. Pancreatic STAT5 activation promotes Kras G12D-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-332225↗
  4. Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. Co-author DOI 10.1016/j.ccell.2023.09.008↗
  5. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04742-y↗
  6. Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT? Co-author DOI 10.1186/s40644-023-00528-z↗
  7. A Tumor-Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer. Last author DOI 10.1002/smll.202101208↗
  8. Oxidative stress induces monocyte-to-myofibroblast transdifferentiation through p38 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.41↗
  9. Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbrc.2020.02.042↗
  10. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant… Co-author DOI 10.1038/s41416-020-01046-6↗
  11. Co-inhibition of the TGF-β pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti… Last author DOI 10.1039/d0bm00916d↗
  12. Characterization of Oral Microbiome and Exploration of Potential Biomarkers in Patients with Pancreatic Cancer. Co-author DOI 10.1155/2020/4712498↗
  13. A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio. Co-author DOI 10.7150/jca.26187↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xin Huang · 4 shared papers, 2018–2024 · strength 0.48
  2. Shengping Li · 4 shared papers, 2018–2024 · strength 0.48
  3. Chaobin He · 4 shared papers, 2018–2024 · strength 0.48
  4. Shuxin Sun · 3 shared papers, 2020–2024 · strength 0.39
  5. Robert M. Straubinger · 2 shared papers, 2020–2024 · strength 0.37
  6. Yize Mao · 2 shared papers, 2020 · strength 0.21
  7. Yunda Song · 2 shared papers, 2018–2020 · strength 0.19
  8. Zhihao Wu · 1 shared paper, 2024 · strength 0.18
  9. Xiangjun Meng · 1 shared paper, 2024 · strength 0.18
  10. Qing Xia · 1 shared paper, 2024 · strength 0.18
  11. Wenquan Wang · 1 shared paper, 2024 · strength 0.18
  12. Liang Liu · 1 shared paper, 2024 · strength 0.18
  13. Yuli Lin · 1 shared paper, 2024 · strength 0.18
  14. Xuguang Yang · 1 shared paper, 2024 · strength 0.18
  15. Fengxiao Xie · 1 shared paper, 2024 · strength 0.18
  16. Guangmei Yan · 1 shared paper, 2024 · strength 0.18
  17. Jing Cai · 1 shared paper, 2024 · strength 0.18
  18. Jianping Lu · 1 shared paper, 2023 · strength 0.18
  19. Chao Ma · 1 shared paper, 2023 · strength 0.18
  20. Yun Bian · 1 shared paper, 2023 · strength 0.18
  21. Yufei Chen · 1 shared paper, 2023 · strength 0.18
  22. Panpan Yang · 1 shared paper, 2023 · strength 0.18
  23. Chengwei Shao · 1 shared paper, 2023 · strength 0.18
  24. Yu Jiang · 1 shared paper, 2023 · strength 0.17
  25. Ningzhen Fu · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.